Video Programs

Addressing Treatment Challenges in Chronic Graft-Versus-Host Disease

Artificial intelligence (AI) has the potential to transform biomarker testing in early-stage NSCLC by streamlining data analysis, improving interpretation of complex genomic profiles, and predicting actionable mutations from imaging or pathology data.

The KEYNOTE-775 study confirms long-term benefits of Lenvatinib and Pembrolizumab for recurrent endometrial cancer, showing sustained survival rates and efficacy.

This preview introduces the central themes of the upcoming Evolving Paradigms in Oncology program focused on targeted therapies and CELMoD agents in multiple myeloma. Dr. Nisha Joseph offers an early look at the questions that guide current treatment choices, the place of next generation CELMoD agents, and the way clinicians think about patient selection. The teaser sets the stage for a deeper conversation that will review clinical evidence, safety features, and practical points that influence decisions in daily practice. Viewers will gain an early sense of the topics and insights that will be explored in full during the complete expert discussion.

Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia at the 2025 ASH Meeting.

Liquid biopsy using circulating tumor DNA (ctDNA) is emerging as a valuable tool in early-stage NSCLC, with the potential to complement or, in some cases, substitute for tissue-based testing.

Current NCCN guidelines for early-stage NSCLC recommend testing for key biomarkers to guide decisions regarding adjuvant targeted therapy or immunotherapy.

Explore the latest trials on eltrombopag and elritercept, promising new treatments for low-risk MDS and CMML with TET2 mutations.

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, enhancing treatment strategies.

A recent study highlights the benefits of early luspatercept treatment for patients with hemoglobin above 8, improving outcomes before transfusion dependency.

A recent study highlights the effectiveness of Luspatercept in first-line treatment, showing significant patient benefits and real-world evidence supporting its use.

A recent analysis reveals that low-risk MDS patients with earlier-stage profiles respond better to luspatercept, suggesting earlier treatment benefits.

A recent study explores inflammatory profiles in low-risk MDS, revealing distinct patient categories and implications for treatment strategies.

A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment strategies.

Explore the clinical considerations for choosing between ESAs and luspatercept in treating low-risk MDS, focusing on efficacy and patient convenience.

Explore the advantages and challenges of long-term red blood cell transfusions for low-risk MDS patients, focusing on quality of life and treatment options.

Exploring the impact of inflammation in MDS, this article highlights the need for novel therapies to enhance patient quality of life.

Discover how a metal statin offers a promising backup treatment for MDS patients, enhancing transfusion outcomes while requiring careful monitoring.

Luspatercept emerges as a preferred treatment for low-risk MDS, enhancing hemoglobin levels and quality of life, even in diverse patient subgroups.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management to avoid complications like iron overload.

Understanding MDS risk classification enhances patient care, focusing on tailored therapies and improving quality of life through effective treatment strategies.

Panelists discuss how emerging targeted agents are poised to reshape the therapeutic landscape for EGFR-mutant NSCLC in the coming years.

Panelists discuss how proactive sequencing strategies optimize long-term outcomes in EGFR-mutant non–small-cell lung cancer (NSCLC) by anticipating resistance patterns.

Panelists discuss how patient-centered counseling and shared decision-making shape personalized treatment journeys in EGFR-mutant non–small-cell lung cancer (NSCLC).

Panelists discuss how adherence to guidelines and vigilant imaging support optimal management of CNS disease in EGFR-mutant non–small-cell lung cancer.